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Abstract: Extracts made from the leaves of the mango food plant (Mangifera indica L., Anacardiaceae) 
have a long history of medicinal usage, most likely due to particularly high levels of the polyphenol 
mangiferin. In rodent models, oral mangiferin protects cognitive function and brain tissue from a 
number of challenges and modulates cerebro-electrical activity. Recent evidence has confirmed the 
latter effect in healthy humans following a mangiferin-rich mango leaf extract using quantitative 
electroencephalography (EEG). The current study therefore investigated the effects of a single dose 
of mango leaf extract, standardised to contain >60% mangiferin (Zynamite®), on cognitive function 
and mood. This study adopted a double-blind, placebo-controlled cross-over design in which 70 
healthy young adults (18 to 45 years) received 300 mg mango leaf extract and a matched placebo, 
on separate occasions, separated by at least 7 days. On each occasion, cognitive/mood assessments 
were undertaken pre-dose and at 30 min, 3 h and 5 h post-dose using the Computerised Mental 
Performance Assessment System (COMPASS) assessment battery and the Profile of Mood States 
(POMS). The results showed that a single dose of 300 mg mango leaf extract significantly improved 
performance accuracy across the tasks in the battery, with domain-specific effects seen in terms of 
enhanced performance on an ‘Accuracy of Attention’ factor and an ‘Episodic Memory’ factor. 
Performance was also improved across all three tasks (Rapid Visual Information Processing, Serial 
3s and Serial 7s subtraction tasks) that make up the Cognitive Demand Battery sub-section of the 
assessment. All of these cognitive benefits were seen across the post-dose assessments (30 min, 3 h, 
5 h). There were no interpretable treatment related effects on mood. These results provide the first 
demonstration of cognition enhancement following consumption of mango leaf extract and add to 
previous research showing that polyphenols and polyphenol rich extracts can improve brain 
function. 
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1. Introduction 
The roots, leaves, fruit and bark of the food plant Mangifera indica (mango) have a long history 
of therapeutic use within traditional medicinal systems for a wide range of conditions. For example, 
extracts, teas and infusions made from mango leaves have been used for the treatment of diabetes, 
malaria, diseases of the digestive system, lungs, and kidneys, and as a topical treatment for wounds 
and burns [1]. The bioactivity of mango leaf extracts may be due to particularly high levels [2] of 
xanthones. This group of polyphenols are found in a restricted group of plant species [3], including 
members of the Hypericum genus that provide us with a number of medicinal herbal extracts [4], but 
they are rarely consumed in the diet, with only a few exceptions other than mango itself (e.g., [5]). 
The predominant member of this structural group in mango leaf is mangiferin, a xanthone glucoside 
that has been shown to have potential anti-inflammatory, antioxidant, immunomodulatory, 
neuroprotective, antiproliferative, antidiabetic, DNA protective, and hypoglycaemic properties [6–
10]. 
Whilst structurally distinct from the flavonoids and other polyphenols that are ubiquitous in 
plant derived foods, mangiferin [8,11–14] likely owes its beneficial bioactivity to some similar 
mechanisms of action as found in the wider polyphenol group class [15], including interactions with, 
and modulation of, diverse components of a wide range of mammalian cellular signal transduction 
pathways. These pathways, in turn, control gene transcription and a plethora of cellular responses, 
including cell proliferation, apoptosis, and the synthesis of growth factors, and vasodilatory and 
inflammatory molecules. In the central nervous system, specific additional interactions attributed to 
polyphenols include direct neurotransmitter and neurotrophin receptor and signalling pathway 
interactions, and increased synthesis of neurotrophins and vasodilatory molecules, which, in turn, 
foster angiogenesis/neurogenesis [15–20]. These mechanisms potentially underlie the observation of 
consistent beneficial cardiovascular effects from meta-analyses of multiple intervention studies [21–
23], and demonstrations of improved cognitive function [24–28], following diverse polyphenols. 
In line with these mechanistic cellular effects, rodent studies have demonstrated that a single 
administration of mangiferin can improve memory in uncompromised rats [29] and that either single 
doses or extended supplementation with mangiferin can attenuate the memory deficits or 
depressive/anxiety behaviours associated with a range of brain insults and challenges. This includes 
the cholinergic antagonist scopolamine [30], sleep deprivation [31], the injection of 
lipopolysaccharides [32] and aluminium chloride-induced neurotoxicity in mice [9]. Consistent ex 
vivo evidence focussing on the hippocampus also shows that mangiferin can protect rodent neuronal 
tissue from the increase in inflammatory cytokines [9,30–32] and the decrease in neurotrophins such 
as brain-derived neurotrophic factor (BDNF) [9,31], associated with multifarious brain insults. 
Similarly, mangiferin has been shown to protect the rodent brain from lead-induced structural 
damage and decrease oxidative stress via interactions within the Nrf2 signalling pathways in rats 
[10]. 
A number of recent studies have assessed the potential efficacy of a mango leaf extract 
standardized to a minimum of 60% mangiferin (Zynamite®). In terms of physical performance, 
several of these studies have assessed the ergogenic effects in humans of both acute [33–36] and 
longer-term supplementation [34] with this mango leaf extract combined with the polyphenols 
luteolin or quercetin. This research has demonstrated an improved performance during high 
intensity exercise [33–35], increased brain oxygenation [33,34], maximal aerobic capacity [33], 
increased muscle oxygen extraction [34,35] and the attenuation of muscle damage and improvements 
in the time course of decreased muscle performance [37]. 
With regard to brain function, in rats, oral administration of mango leaf extract attenuated 
electroencephalography (EEG) power measured via implanted electrodes (frontal cortex, 
hippocampus, striatum, reticular formation) across the spectra and brain regions under investigation, 
with the most striking findings in the alpha and beta wavebands. These effects were synergistically 
increased by the co-administration of caffeine. A concomitant ex vivo study also demonstrated that 
7 days supplementation with the mango leaf extract lead to increased hippocampal pyramidal cell 
excitability [38]. In a subsequent multi-disciplinary series of studies [39], both the ex vivo 
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hippocampal excitability and the attenuation of EEG spectral power across brain regions in rats were 
confirmed both for mango leaf extract and mangiferin, confirming this polyphenol as the likely active 
component of the extract. In two subsequent pilot studies (also reported in [39]), both involving 16 
healthy young humans, quantitative EEG was employed at rest and during cognitive task 
performance 90- and 60-min post-dose respectively. In the first study, in comparison to control, 
mango leaf extract resulted in modest reductions in ‘eyes open’ power in delta and theta power, and 
a more pronounced increase in power during cognitive task performance, with significant increases 
in all wavebands across scalp electrodes interrogating the association cortex. These results were 
supported by more modest EEG changes in the second study, but no evidence of a synergistic 
relationship with caffeine. Cognitive task performance and mood were not significantly modulated 
by mango leaf extract. 
The extant literature demonstrating functional benefits following polyphenol consumption, and 
the previous rodent and pilot human studies assessing the effects of mangiferin and mango leaf 
extract described above, suggest that a mango leaf extract with high levels of the polyphenol 
mangiferin may exert beneficial effects on human brain function, including the enhancement of 
cognitive function. The current exploratory, double-blind, placebo-controlled, balanced crossover 
study therefore assessed the effects of a single dose of mango leaf extract (Zynamite®) on cognitive 
function and psychological state 30 min, 3 h and 5 h post-dose in a large sample of healthy adults. 
2. Methods 
2.1. Design 
This study adopted a randomised, double-blind, placebo-controlled, balanced crossover design, 
in which the acute effects of a single dose of 300 mg mango leaf extract and placebo were assessed on 
cognitive function and psychological state/mood at 30 min, 3 h and 5 h post-dose. All study 
procedures were reviewed and approved by Northumbria University’s Department of Psychology 
Ethics Committee (Ref: 17741) and were conducted according to the principles of the Declaration of 
Helsinki. The trial was pre-registered at ClinicalTrials.gov (NCT04299217). 
2.2. Participants 
The required sample size for the study (N = 72) was calculated (GPower 3.0) on the basis of 
delivering adequate power (0.8) to detect a small effect size (f = 0.1). The power to detect the 
anticipated medium effect size (f = 0.25) exceeded 0.95. 
A total of 75 participants were randomised. Three participants subsequently withdrew from the 
study after completing one testing visit. Two participants were removed from the dataset during 
blind data review due to a persistent inability to achieve performance criteria across tasks. 
The final per-protocol analysis sample therefore comprised 70 participants (F 37/M 33; mean age 
26.9 years, range 18–45 years; 5 vegetarians and 1 vegan). All participants self-reported that they were 
healthy and free from any relevant medical condition or disease, including psychiatric and 
neurodevelopmental disorders; that they were not taking any prescription or illicit drugs, food 
supplements or nicotine containing products; that they were not pregnant, lactating or seeking to 
become pregnant. Participants were also excluded if they consumed >500 mg caffeine per day (>6 × 
150 mL cups of filter coffee), had high blood pressure (>systolic 159 mm Hg or diastolic 99 mm Hg) 
or had a body mass index outside of the range 18.5–35 kg/m2. Participant dispositions are shown in 
Figure 1. 
The final number of participants’ data points (excluding missing data and data points removed 
during blind data review) included in the analysis of data from each individual outcome are shown 
in the relevant tables. 
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Figure 1. Participant disposition. 
2.3. Treatments 
Zynamite® mango leaf extract is comprised of components within the following ranges: 
mangiferin—60–65%; homomangiferin—3–5%; isomangiferin—up to 1%; leaf polysaccharides—6–
20%; hydrolysable and non-hydrolysable tannins—up to 1%; fibre, minerals, moisture—6 to 15%. 
Details of the manufacturing process are provided elsewhere [39]. 
Participants were randomly allocated to receive 300 mg mango leaf extract or placebo 
(maltodextrin) in methylcellulose capsules of identical appearance, during each of their two 
assessment days. Testing days were separated by a minimum of 7 days to ensure washout. The order 
in which participants received the two interventions was counterbalanced across the group via 
random allocation to a counterbalancing schedule. Individual treatments were delivered to the trial 
facility in individual sealed plastic envelopes, labelled with the participants’ randomisation numbers 
and visit (1 or 2) according to the computer-generated double-blind randomisation schedule. 
There were no significant adverse events that could be linked to administration of the treatments 
and no significant difference in the incidence of minor adverse events (e.g., mild headache) between 
the placebo and mango leaf extract treatments. 
2.4. Psychological Measures 
2.4.1. Cognitive Tasks 
All of computerised cognitive/mood assessments were identical, and were carried out via laptop 
computers and response boxes using the Computerised Mental Performance Assessment System 
(COMPASS, Northumbria University, Newcastle upon Tyne, UK). This software platform 
incorporates the presentation of classic and custom computerised cognitive tasks, with fully 
randomised parallel versions of each task delivered at each assessment for each individual. A similar 
selection of tasks has previously been shown to be sensitive to diverse nutritional interventions [40–
43]. Within the 60-min assessment the participants also completed a 30-min component known as the 
Cognitive Demand Battery (CDB), which comprises the prolonged repetition of a series of demanding 
tasks that assess working memory, executive function and attention. The objective of this battery is 
to assess the impact of treatment on speed/accuracy and mental fatigue during continuous 
performance of cognitively demanding tasks. The CDB has also been shown to be sensitive to 
modulation by a wide range of nutritional interventions [43–46]. The individual tasks making up the 
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cognitive assessment (including the CDB) are shown in Figure 2 and described in more detail in the 
online Supplementary Materials (Section I). 
Figure 2 also shows the contribution of individual tasks to the principal performance measures, 
which were derived by averaging the data (either msec for speed, or % correct/maximum score for 
accuracy) from individual tasks into the following global performance outcomes: ‘Speed of 
Performance’ and ‘Accuracy of Performance’; and the following cognitive domain factor scores 
‘Speed of Attention’, ‘Accuracy of Attention’, ‘Speed of Memory’, ‘Working Memory’, and ‘Episodic 
Memory’. The derivation of the global scores and cognitive factors are described in more detail in the 
online Supplementary Materials (Section II). These global measures and cognitive domain factors 
have been shown to be sensitive to nutritional manipulations previously [40–42]. 
 
Figure 2. Cognitive assessments. The running order of tasks and their contribution to the cognitive 
factors (to the right) and global performance measures (to the left) derived from the overall battery. 
The same assessment was completed at the pre-treatment baseline and at 30 min, 3 h and 5 h post-
dose on each assessment day. The selection of tasks took a total of 60 min to complete, with the 
Cognitive Demand Battery comprising 30 min of this. The individual tasks are described in more 
detail in the supplementary online materials (Section I). Rapid Visual Information Processing task 
(RVIP). Visual analogue scale (VAS). 
2.4.2. Mood and Psychological State 
Before each cognitive assessment, participants completed the Profile of Mood States (POMS-2) 
Adult Short Form [47]. As part of the COMPASS battery, and before the cognitive tasks, participants 
completed the Visual Analogue Mood Scales (VAMS), a set of 18 visual analogue scales anchored by 
pairs of antonymic mood/state adjectives (e.g., Alert–Inattentive; Lethargic–Energetic). Participants 
rated where they would position themselves between the adjectives anchoring each line according to 
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how they felt at that moment. The individual item scores were combined to give an average (% along 
the line) score on three factors that had previously been derived by factor analysis: ‘Alertness’, 
‘Tranquillity’ and ‘Stress’. After the cognitive tasks participants also completed a further four stress 
visual analogue scales (S-VAS) that required them to rate their current psychological state between 
‘not at all’ and ‘extremely’ with regard to their levels of stress, anxiety, calmness and relaxation. These 
were combined into two scores ‘stress/anxiety’ and ‘calm/relaxed’ with a higher score (average % 
along the line) representing more of the descriptor. 
2.5. Procedure 
Participants were required to attend the Brain, Performance and Nutrition Research Centre 
(Northumbria University) for three visits. The first visit comprised a screening and training session 
where, once written informed consent had been obtained, participants were screened according to 
the inclusion/exclusion criteria. Eligible participants then provided lifestyle and demographic data 
and their height, weight, waist to hip ratio and blood pressure were measured. They completed a 
short training session in which they practiced the cognitive tasks. Practice took the form of three 
repetitions of shortened versions of the COMPASS cognitive tasks, followed by the completion of the 
full-length, 60-min battery twice. During and at the end of the practice session, participants’ 
performance was checked against standard minimum performance criteria and additional guidance 
was provided as necessary. At the end of this visit, participants were briefed as to what to expect on 
testing visits and were provided with pre-testing instructions. 
Within four weeks of the screening visit, participants returned to the laboratory for their first 
testing visit at an agreed time in the morning that remained consistent across all testing visits. A 
maximum of 5 participants were tested on any day, and all participants were visually isolated in 
individual testing booths. Participants arrived at the laboratory having refrained from alcohol for 24 
h, caffeine overnight and having consumed a simple breakfast of cereal and/or toast at home no later 
than an hour before arrival. Once participants arrived at the lab, they were not permitted to eat any 
food (aside from food items provided by the study staff) or drink (except for water) or chew gum. 
Continued compliance with the inclusion/exclusion criteria was assessed. This was followed by 
completion of the POMS and a 60-min computerised cognitive and mood assessment (COMPASS—
including the 30-min Cognitive Demand Battery (CDB), Visual analogue mood scales (VAMS) and 
stress visual analogue scales (S-VAS)—see Figure 2.). Cognitive tasks were completed with the 
participants visually isolated from each other. After the first cognitive/mood assessment, participants 
consumed their treatment for the day and completed cognitive/mood assessments, identical to the 
above, commencing at 30 min, 3 h and 5 h post-dose. An additional, brief, 5-min assessment 
investigating the participants’ response to a laboratory stressor, plus pre/post-dose blood sampling 
for half of the participants (for quantification of neurotrophins and catecholamines), took place after 
the pre-treatment and 30-min post-dose cognitive/mood assessments (For methodology see [48]), the 
results of this theoretically distinct investigation are to be reported elsewhere). All participants were 
scheduled to return to the laboratory 7 days later, with a maximum allowable leeway of an additional 
7 days should exceptional circumstances arise in the meantime. This second testing day was identical 
to the previous day, with the exception that participants consumed a different treatment on each of 
the two days. The timelines of the testing day are presented in Figure 3. 
 
Figure 3. The timelines of the testing day for individual participants, showing the core cognitive 
assessment schedule. Profile of Mood States (POMS), 5 min Observed Multi-Tasking Stressor (*OMS) 
(methodology and results to be reported elsewhere). 
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Participants were provided with a standardised lunch (comprising a cheese sandwich on white 
bread, crisps and a custard pot) between the 180 and 300 min post-dose assessments and were given 
the option of a snack (hot decaffeinated tea or coffee and digestive biscuits) after completion of the 
stressor following the 30-min post-dose assessment. No alternative drinks, snacks or lunches were 
permitted. 
2.6. Analysis 
The study statistical analysis plan was formulated before the completion of data collection. 
Given the exploratory nature of the study, and the lack of any relevant human data, a small sub-set 
of primary outcomes was not pre-defined. Given the study intervention and objectives, a per protocol 
analysis was deemed the most appropriate. 
All outcomes were analysed using SPSS (version 24.0, IBM corp., Armonk, NY, USA). During 
blind data review a number of participants’ individual task datasets were removed due to technical 
or performance issues (for details of the issues and number of datasets involved see supplementary 
online materials). Prior to the primary analysis of the effects of treatment, pre-dose baseline 
differences between treatment were investigated by one-way (treatment group [placebo v mango leaf 
extract]) paired t tests, or in the case of the Cognitive Demand Battery (CDB) two-way (treatment x 
repetition) ANOVA. There were no significant differences between treatment groups at baseline. 
For all cognitive and mood measures, the primary analysis of post-dose data was by Linear 
Mixed Models (LMM) using the MIXED procedure in SPSS (version 22.0, IBM corp.) with pre-dose 
baseline data for each outcome included as a covariate. For all LMM analyses, the ‘compound 
symmetry’ covariance structure provided the best fit, with the exception of ‘mental fatigue’ from the 
CDB for which an autoregressive covariance structure (AR1) was more appropriate. 
For the cognitive outcomes derived from the COMPASS battery and the mood outcomes, terms 
were fitted for treatment (placebo/mango leaf extract) and assessment (30 min, 3 h, 5 h) and their 
interaction. For the CDB measures an additional ‘repetition’ term was added along with the 
appropriate interactions. Given that the treatment orders were balanced across the sample, or exactly 
or nearly balanced with regard to the participants contributing to each outcome (and given that 
treatment carry-over effects were highly unlikely), treatment order was not included as a factor in 
the analysis. 
In order to establish the time course of any effects, pre-defined planned comparisons were 
conducted between treatments at each assessment time point (30 min, 3 h, 5 h) with a Bonferroni 
adjustment for the number of comparisons undertaken per outcome (i.e., 3). Only those planned 
comparisons conducted on data from outcomes that evinced a significant treatment related main or 
interaction effect are reported below. 
3. Results 
3.1. Cognitive Task Global and Factor Outcomes 
The global outcomes and cognitive factors derived from the COMPASS battery showed that 
mango leaf extract resulted in significantly improved accuracy of performance across tasks and 
throughout the testing day (i.e., at 30 min, 3 h and 5 h post-dose). See Figure 4 below. There was a 
main effect of treatment on the global Accuracy of Performance measure (representing data from the 
eleven tasks that return % accuracy/maximum score data) (F (1, 335) = 22.8, p < 0.001). Reference to 
the planned comparisons at each assessment showed that this effect was evident throughout the post-
dose testing period (30 min p = 0.03, 3 h p = 0.02, 5 h p = 0.009). There were also significant main effects 
in terms of improved accuracy following mango leaf extract on the Accuracy of Attention factor (F 
(1, 315) = 16.697, p < 0.001) and the Episodic Memory factor (F (1, 345) = 6.94, p = 0.009). With regard 
to the time course of these effects, whilst the Bonferroni adjusted comparisons of Episodic Memory 
scores did not reach significance during the individual assessments, Accuracy of Attention was 
improved at both the 3 h (p = 0.048) and 5 h (p = 0.01) post-dose assessments. Data (plus F score and 
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p) for the cognitive outcomes derived from the COMPASS battery are presented in the online 
Supplementary Materials (Table S1.). 
 
Figure 4. The effects of mango leaf extract on the global outcome measures and factor scores derived 
from the Computerised Mental Performance Assessment System (COMPASS) cognitive tasks. Left-
hand panels show the main effect of treatment averaged across assessments; middle panels show the 
pre-dose baseline scores; right-hand panels show time course data from each post-dose assessment 
for those measures that saw significant effects on the planned comparisons (Bonferroni). The global 
Accuracy of Performance measure represents averaged data from the eleven tasks from the battery 
that return % accuracy/maximum score data: Accuracy of Attention represents averaged % accuracy 
data from the five attention tasks; and Episodic Memory represents averaged % accuracy/recall across 
the four long-term memory tasks. *, p < 0.05; **, p < 0.01, ***, p < 0.001 versus placebo. Number of 
participants contributing to the measure: Accuracy of Performance, n = 68, Episodic Memory, n = 70, 
Accuracy of Attention, n = 64. 
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3.2. Cognitive Demand Battery (CDB) 
In keeping with the improved accuracy seen across the COMPASS task factors, performance in 
all three CDB tasks was improved across the testing day following mango leaf extract. See Figure 5. 
The Rapid Visual Information Processing task (RVIP) was improved across assessments in terms of 
% of targets accurately detected (F (1, 1071) = 23.186, p < 0.001) with planned comparisons showing 
that these effects were apparent at the 30 min (p = 0.047) and 5 h (p = 0.001) assessments, with a trend 
towards the same effect at 3 h post-dose (p = 0.059). Performance was also improved on both the Serial 
3s task (F (1, 1156) = 10.9, p < 0.001) and Serial 7s task (F (1, 1156) = 9.642, p = 0.002) in terms of number 
of correct subtractions across the testing day. Comparisons at each assessment showed that while the 
differences between groups did not reach significance during any individual assessment for the Serial 
7s task, Serial 3s performance was enhanced at the 3 h assessment (p = 0.014), with a trend towards 
the same at 30 min post-dose (p = 0.088). There was no effect on ratings of mental fatigue during 
completion of the battery. Data (plus F score and p) for the CDB outcomes are presented in the online 
Supplementary Materials (Table S2.). 
 
Figure 5. The effects of mango leaf extract on the Cognitive Demand Battery outcomes. Each task was 
repeated three times per assessment (total Cognitive Demand Battery (CDB) completion time, 30 min 
per assessment). Left-hand panels show the main effect of treatment averaged across 
assessments/repetitions; middle panels show the pre-dose baseline scores averaged across the three 
repetitions; right-hand panels show time course data from each post-dose assessment (averaged 
across the three repetitions per assessment) for those measures that saw significant effects on the 
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planned comparisons (Bonferroni) of mango leaf extract versus placebo. t, p < 0.1; *, p < 0.05; ***; p < 
0.001 in comparison to placebo. Number of participants contributing to the measure: RVIP, n = 64, 
Serial 3s/7s, n = 69. 
3.3. Mood and Psychological State 
There were no effects of treatment on any mood parameter (VAMS, S-VAS, POMS), with the 
exception of reduced calm/relaxed ratings on the S-VAS following mango leaf extract across testing 
assessments (F (1, 345) = 5.44, p = 0.02). See Figure 6. There were no significant differences on the 
comparisons made at each assessment for this outcome. Data from the POMS, VAMS and S-VAS data 
are presented in the online Supplementary Materials (Table S3.). 
 
Figure 6. The effects of mango leaf extract on the calm/relaxed stress visual analogue scales (S-VAS) 
measure. There were no significant differences on the planned comparisons of data from each 
assessment. *, p < 0.05 in comparison to placebo. 
4. Discussion 
In the current study a single dose of mango leaf extract (Zynamite®) lead to significant, broad 
improvements in performance across a battery of cognitive tasks throughout the 6 h following 
consumption. There were no interpretable benefits found for any measure of mood/psychological 
state. 
Cognitive improvements were seen on the global Accuracy of Performance measure, which 
comprised averaged % accuracy or % maximum score data from 11 computerised tasks. It was also 
seen more specifically in the cognitive sub-factors ‘Accuracy of Attention’, representing the overall 
% accuracy whilst performing the five attention tasks (excludes simple reaction time) within the 
battery and ‘Episodic Memory’, which represents the % recall or accuracy of the four long-term 
memory tasks. Performance benefits were also seen across all three of the tasks that make up the 30-
min Cognitive Demand Battery, with improved RVIP accuracy and increased numbers of correct 
subtractions generated by participants on both the Serial 3s and Serial 7s tasks. These cognitive 
effects, taken as a whole, were evident as main effects across the post-dose testing day, which 
comprised 60 min assessments starting at 30 min, 3 h and 5 h post-dose, without any clear pattern of 
augmentation or attenuation over time. There were no benefits seen in terms of increased speed of 
task performance on the timed tasks, or indeed on the mood and psychological state measures. 
Clearly, one question raised by these results is whether the effects seen here represent a truly 
global improvement in accuracy across cognitive domains, or whether they simply reflect the 
consequences of improved attention. Certainly, attention and episodic memory are inter-related, with 
enhanced attention leading to improved encoding and retrieval of information. It has been suggested 
that episodic memory processes are themselves, to an extent, ‘acts of attention’ [49]. As the attention 
and episodic memory tasks comprised the majority of the tasks that contributed to the global 
42
44
46
48
50
52
54
Calm/Relaxed VAS
*
A
v
e
ra
g
e
 %
  
a
lo
n
g
 V
A
S
Mango extract placebo
Nutrients 2020, 12, 2194 11 of 16 
 
accuracy measure, it is possible that the improvements to the latter are simply a reflection of broad 
improvements to attention. However, the improvements in Serial 3s and Serial 7s subtraction task 
performance would be more difficult to accommodate solely within an attention framework. Whilst 
both subtraction tasks have attentional components, they draw more heavily on both working 
memory and executive function, particularly the more difficult Serial 7s, which requires greater 
executive resources in order to carry out the more complex manipulation of numbers [24]. Enhanced 
performance on these tasks, alongside improved accuracy across the tasks, therefore, seems to 
confirm that the benefits of mango leaf extract were seen broadly across cognitive domains. 
The results also suggest that the modulation of cerebro-electrical activity (measured using EEG) 
seen in healthy adults following a single dose of Zynamite mango leaf extract [39] is most likely 
indicative of a benefit to brain function. The cognitive benefits seen here are broadly in line with 
previous demonstrations of improved cognitive function following both acute [24–26] and chronic 
administration [27,28] of polyphenol rich extracts. Several polyphenol studies also employed the 
Cognitive Demand Battery used here (but at a single post-dose time point), with demonstrations of 
improved performance across all three tasks following cocoa-flavanols [24], improved Serial 3s 
performance following fruit flavanols [50], but no benefits following resveratrol [51]. Of note, the 
global performance measures derived from the cognitive tasks utilised here have proved sensitive to 
the acute and chronic administration of a Nepalese pepper extract [42] and acute administration of a 
green oat extract to middle-aged adults [41]. However, both of these interventions contain other 
potentially bioactive phytochemicals alongside polyphenols, and in both cases global speed of 
performance was enhanced, rather than the improved global accuracy seen in the current study. 
Previous research has demonstrated similarities in EEG cerebro-electrical response following 
both mango leaf extract and caffeine in rodents [38], but somewhat different responses to these two 
individual treatments in humans [39]. The cognitive effects of caffeine comprise modest but 
consistent improvements that are restricted to the performance of tasks measuring attention, with no 
reliable effect on other cognitive domains including long-term (episodic) memory [52–55]. Similarly, 
the duration of the effects seen following mango leaf extract do not follow the time course of caffeine’s 
effects, which would become apparent by 30 min post-dose and would be expected to attenuate by 6 
h post-dose. It is therefore notable that the pattern of cognitive benefits seen in the present study 
following the mango leaf extract are broader and longer lasting than those that would be expected 
after caffeine. 
In terms of mechanism of action, a recent study investigating receptor binding and brain relevant 
enzyme inhibition found that mangiferin only significantly inhibited catechol-O-methyl transferase 
(COMT), the enzyme responsible for the degradation of catecholamine neurotransmitters [39]. 
Several other polyphenols that also feature a catechol moiety, including flavanols and oleacein, have 
also been shown to inhibit COMT [56,57]. COMT’s catabolic pathway is most prevalent in brain tissue 
with low concentrations of catecholamine reuptake transporters, and therefore COMT inhibition 
predominantly affects dopaminergic function in the prefrontal cortex and hippocampus [58], 
potentially leading to improved working memory, selective attention, and executive function [59]. 
Clearly, the benefits seen in the current study correspond with these cognitive domains. However, 
whilst there is some evidence that COMT inhibitors may modulate these aspects of cognitive 
function, the overall pattern is for their effects to be bidirectionally moderated by COMT genotype 
(val158met polymorphism) [59–61]. COMT inhibition per se is therefore unlikely to be the primary 
mechanism underpinning the straightforward cognitive benefits seen here across a sample of mixed 
COMT genotypes. 
Other potential ‘direct’ brain-relevant mechanisms of action previously established for 
mangiferin include acetylcholinesterase (AChE) inhibition [30,62] or other potential cholinergic 
mechanisms of action [63]. Increased acetylcholine activity would be expected to have a beneficial, 
inter-related effect on both focussed attention and memory consolidation/retrieval [64] and, 
therefore, could encompass many of the effects seen in the current study. However, it is equally likely 
that the effects seen here may be related to ‘indirect’ interactions within mammalian cellular signal 
transduction pathways, a property that mangiferin shares with other polyphenols [8,11–14]. These 
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interactions potentially drive downstream modulation of neuroinflammation, neurotransmission, 
neurotrophin receptor and signalling pathway interactions, and increased synthesis of neurotrophins 
and vasodilatory molecules, leading to increased angiogenesis/neurogenesis and local cerebral blood 
flow [15–19]. These indirect cellular interactions may underlie the consistent demonstrations in 
humans of increased cerebral blood-flow [51,65–69] and peripherally measured brain-derived 
neurotrophic factor [26] seen following diverse polyphenols. Again, potentially diffuse beneficial 
effects within the brain could be conceived as potentially leading to broad benefits to cognitive 
function across domains, as seen here. 
Clearly, a strength of the current study is that it represents the first concerted investigation of 
the effects of mangiferin, or indeed any xanthone glycoside, on human cognitive function. 
Conversely, this was, by its nature, an exploratory study, and the absence of pre-defined primary 
outcomes, due to a lack of previous data to guide their formulation, could be considered a limitation. 
Certainly the absence of primary endpoints allows a greater freedom for the interpretation of the 
results than will be enjoyed in future research, and it is hoped that the results of the current study 
will be useful in terms of directing the research questions and outcomes addressed by more studies 
involving this compound.  
It should also be acknowledged that the results herein relate to a molecule, or group of molecules 
(xanthones) that are unlikely to be encountered in meaningful quantities in the typical diet, and 
therefore the results can only realistically be extrapolated to supplementation with mangiferin-rich 
extracts. Whilst the results tell us little about the benefits of polyphenols consumed as part of the 
everyday diet it might be noteworthy that the dose of 300 mg employed here contained an amount 
of polyphenols that is achievable through the consumption of polyphenol rich foods. 
In conclusion, a single dose of mango leaf extract (Zynamite®) with high levels of the polyphenol 
mangiferin, lead to broad improvements in cognitive function that were seen across assessments 
spanning from 30 min to 6 h post-dose. These benefits were seen most strikingly in terms of 
participants’ improved attention and long-term memory task performance and in their extended 
performance of cognitively demanding tasks, including those requiring executive function resources. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/12/8/2194/s1. 
Section I: Individual COMPASS and CDB cognitive task descriptions. Section II: Derivation of the global 
outcome measures and cognitive domain factors, including notes on lost data. Section III: Table S1. (data from 
global measures and cognitive factors), Table S2. (data from Cognitive Demand Battery), Table S3. (data from 
the mood measures). 
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